Orexigen Therapeutics — Technical Presentation (September 2009)
16 slides from Orexigen Therapeutics's technical presentation, Sep 30, 2009
Slide 1: Empatic Phase 2b Trial Summary
Empatic™ Phase 2b Trial Summary Empatic™ Phase 2b Trial Summary Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements Forward-Looking Statements Orexigen cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "poten
Slide 3: > ~™ a ve
> ~™ a ve OREXIGEN’
Slide 4: Phase 2b Designed to Demonstrate Superiority of Empatic over its Constituents
Empatic Phase 2b Designed to Demonstrate Superiority of Empatic over its Constituents Empatic Phase 2b Designed to Demonstrate Superiority of Empatic over its Constituents Objective: Demonstrate greater weight loss with Empatic over: individual constituents placebo Sample Size: 729 Randomized subjec
Slide 5: Subject Disposition and Analysis Populations
Subject Disposition and Analysis Populations Placebo Bupropion Zonisamide Zonisamide Empatic120 Empatic360 All Randomized Safety Population Intent to Treat Population Completer Population (60%) (66%) (58%) (52%) (58%) (60%) Subject Disposition and Analysis Populations Safety Population: All randomiz
Slide 6: Subject Demographics
Subject Demographics Placebo (N=75) Bupropion (N=81) Zonisamide (N=77) Zonisamide (N=158) Empatic120 (N=81) Empatic360 (N=164) Age (y) 44.2 41.1 45.0 43.9 43.9 44.4 Sex (% Female) 93.3% 88.9% 89.6% 84.8% 81.5% 84.8% Race (% White) 78.7% 67.9% 75.3% 73.4% 81.5% 77.4% Weight (kg) 99.0 100.5 101.6 99.3
Slide 7: OREXIGEN’
is OREXIGEN’ Placebo 8360 2120 Empatic120 Placebo 7360 Empatic360, 0% — — - 0% 1% 1% 2% 2 2% Cl 4% a 3 3% : 3% -2.3% = = ' 8 -4% -4% 3B © B 5% 5% 5 53% 5 6% 6% . & 5 7% 7% 8% 8% -7.5%
Slide 8: Demonstrates Meaningful Weight Loss After 24 Weeks of Therapy
Empatic Demonstrates Meaningful Weight Loss After 24 Weeks of Therapy Empatic Demonstrates Meaningful Weight Loss After 24 Weeks of Therapy 5% Responders (ITT - LOCF) Note: All differences between Empatic and placebo highly statistically significant Mean % Weight Loss (ITT - LOCF)
Slide 9: Demonstrates Early and Progressive Weight Loss
Empatic Demonstrates Early and Progressive Weight Loss Empatic Demonstrates Early and Progressive Weight Loss At 24 weeks, Empatic demonstrates: Clinically meaningful weight loss No evidence of plateau Both Empatic doses appear efficacious and could provide dosing flexibility Note : All differences
Slide 10: Demonstrates Substantial Categorical Weight Loss After 24 Weeks of Therapy
Empatic Demonstrates Substantial Categorical Weight Loss After 24 Weeks of Therapy Empatic Demonstrates Substantial Categorical Weight Loss After 24 Weeks of Therapy Note: All differences between Empatic and placebo statistically significant Placebo (n=53) Empatic120 (n=54) 5% 10% 15% Weight loss ca
Slide 11: Weight Loss is Associated with Improvements in Markers of Cardiometabolic Risk
Empatic Weight Loss is Associated with Improvements in Markers of Cardiometabolic Risk Cardiometabolic Risk Factors Empatic Weight Loss is Associated with Improvements in Markers of Cardiometabolic Risk Cardiometabolic Risk Factors Improvements observed in (1) Waist Circumference Fasting Triglycerid
Slide 12: Appears Generally Well Tolerated
Empatic Appears Generally Well Tolerated Empatic120 (N=93) Empatic360 (N=182) Empatic Appears Generally Well Tolerated Placebo (N=89) Empatic120 (N=93) Empatic360 (N=182) Headache 3.4% 12.9% 14.8% Insomnia 4.5% 15.1% 12.1% Nausea 5.6% 7.5% 12.1% Constipation 0% 6.5% 12.1% Dry Mouth 1.1% 7.5% 10.4% N
Slide 13: Most Adverse Events did not Lead to Discontinuation
Most Adverse Events did not Lead to Discontinuation Empatic120 (N=93) Empatic360 (N=182) Most Adverse Events did not Lead to Discontinuation Placebo (N=89) Empatic120 (N=93) Empatic360 (N=182) Overall Discontinuation Rate 40% 42% 40% Discontinuation due to any adverse event(s) 13.5% 24.7% 23.1% Inso
Slide 14: Safety Experience with Empatic
Safety Experience with Empatic Neuropsychiatric Scales Safety Experience with Empatic Adverse events and laboratory findings appeared to be consistent with the individual components of Empatic No serious adverse events attributed by investigators to study drug No statistically or clinically signific
Slide 15: OREXIGEN’
« OREXIGEN’
Slide 16: Slide 16
Orexigen Therapeutics — Technical Presentation (September 2009) on 6ix